Talimogene laherparepvec, also known as T-VEC, is a genetically modified oncolytic viral therapy approved for the treatment of certain types of cancer, most notably melanoma. It is derived from the herpes simplex virus type 1 (HSV-1) and has been engineered to selectively replicate in and destroy cancer cells while sparing normal cells.
